Associatie tussen de ziekte van Graves en thymushyperplasie.
Recruiting
- Conditions
- Immunodeficiencies
- Registration Number
- NL-OMON25605
- Lead Sponsor
- Erasmus Medical Center, Rotterdam, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
1. Graves' disease;
2. 18-40 years of age.
Exclusion Criteria
1. Use of corticosteroids last three months;
2. Infections during last three months;
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of thymic hyperplasia in patients with Graves' disease,<br>presence of thymic hyperplasia will be analysed with I123 scan 20min and<br>24hours after intake of I123.<br /><br>Outcomes will be compared with a database of healthy people, which is already present.
- Secondary Outcome Measures
Name Time Method Secondary endpoints consist of a change in thymic output, peripheral cell numbers or ratio’s of peripheral T cell<br>subpopulations in comparison to healthy controls.